Enveric signs non-binding term sheets to out-license three compound classes; potential $200M milestones

Enveric Biosciences, Inc.

Three non-binding term sheets signed with undisclosed biotech for exclusive global out-licenses of three compound classes.
Potential total milestone payments and execution fees up to $200M if all development and sales criteria are met.
Royalty rates on each license range from 2.5% to 10% on future sales depending on criteria.
Compounds from Enveric's Psybrary platform library of over 1,000 novel molecules generated using AI drug discovery.
Licensee assumes all future preclinical and clinical development costs for human/animal applications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.